Publications by authors named "Les M Lukavetskyy"
Hematol Oncol
February 2020
Article Synopsis
- BCD-020 is a proposed biosimilar to rituximab, demonstrating similar quality and effectiveness in treating adult patients with indolent lymphomas in a multicenter clinical trial.
- The study involved 174 patients, showing overall response rates of 44.71% for BCD-020 and 41.89% for rituximab, indicating equivalent efficacy between the two treatments.
- Both drugs had comparable safety profiles, with no unexpected adverse reactions and similar patterns in the depletion of B-cells, confirming pharmacokinetic equivalence.
